Synthetic Surfactant CHF5633 compared with Poractant Alfa in the Treatment of Neonatal Respiratory Distress Syndrome: A Multicenter, Double Blind, Randomized, Controlled Clinical Trial

To compare efficacy and safety of a new synthetic surfactant, CHF5633, enriched with surfactant proteins, SP-B and SP-C peptide analogues, with porcine surfactant, poractant alfa for the treatment of respiratory distress syndrome (RDS) in preterm infants.

Source: The Journal of Pediatrics - June 12, 2020 Category: Pediatrics Authors: Rangasamy Ramanathan, Manoj Biniwale, Krishnamurthy Sekar, Nazeeh Hanna, Sergio Golombek, Jatinder Bhatia, Martha Naylor, Laura Fabbri, Guido Varoli, Debora Santoro, Dorothea Del Buono, Annalisa Piccinno, Christiane E. Dammann Tags: Original Articles Source Type: research